Summary
To evaluate the relative role of “diabetogenic” hormones as insulin antagonists in severe derangements of diabetic control, glucagon, cortisol, growth hormone and adrenaline were administered by continuous intravenous infusion, separately and in combination, to ketosis-prone insulin-dependent diabetics (n=11). The amount of insulin required for the assimilation of a 50 g glucose load during the various hormone infusions was determined by means of an automated glucose-controlled insulin infusion system and used as an index of insulin effectiveness. Raising plasma hormone concentrations acutely into the range seen in severe diabetic states (glucagon 517±70 pg/ml; cortisol 32±3 μg/dl; growth hormone 14±3 ng/ml) did not alter significantly blood glucose profile and insulin requirement (control 11.3±1.1 U; glucagon 11.6±2.0 U; cortisol 11.1±0.4 U; growth hormone 12.9±1.4U), except for adrenaline (plasma level 550±192 pg/ml), which caused a marked rise in blood glucose levels and a threefold increase in insulin demand (31.1±3.7 U). Combined infusion of all hormones did not potentiate significantly the latter effect (38.3±4.7 U). The effectiveness of metabolic control by insulin was assessed by a marked decrease in plasma non-esterified free fatty acids and ketone bodies upon its administration after glucose ingestion in all groups studied. It is concluded that from the hormones investigated within this study adrenaline exerts the strongest diabetogenic action during its short term administration followed by that of growth hormone. Whereas it may well be that over-insulinization of the patients by the glucose controlled insulin infusion system has overcome and disguised the smaller diabetogenic effects of cortisol and glucagon.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barnes AJ, Kohner EM, Bloom SR (1978) Importance of pituitary hormones in aetiology of diabetic ketoacidosis. Lancet 1: 1171–1174
Schade DS, Eaton RP (1977) The controversy concerning counter-regulatory hormone secretion. A hypothesis for the prevention of diabetic ketoacidosis? Diabetes 26: 596–601
Müller WA, Faloona GR, Unger RH (1973) Hyperglucagonemia in diabetic ketoacidosis. Am J Med 54: 52–57
Gerich JE, Martin MM, Recant L (1971) Clinical and metabolic characteristics of hyperosmolar nonketotic coma. Diabetes 20: 228–238
Unger RH (1965) High growth-hormone levels in diabetic ketoacidosis: A possible cause of insulin resistance. J Am Med Assoc 191: 149–151
Cryer PE, Daughaday WH (1970) Diabetic ketosis — Serial plasma growth hormone concentrations during therapy. Diabetes 19: 519–523
Christensen NJ (1974) Plasma norepinephrine and epinephrine in untreated diabetics during fasting and after insulin administration. Diabetes 23: 1–8
Waldhäusl W, Kleinberger G, Korn A, Dudczak R, Bratusch-Marrain P, Nowotny P (1979) Severe hyperglycemia: Effect of rehydration on endocrine derangements and blood glucose concentration. Diabetes 28: 577–584
Raskin P, Unger RH (1977) Effects of exogenous hyperglucagonemia in insulin-treated diabetics. Diabetes 26: 1034–1039
Luft R, Cerasi E (1968) Human growth hormone as a regulator of blood glucose concentration and as a diabetogenic substance. Diabetologia 4: 1–9
Perley M, Kipnis DM (1966) Effects of glucocorticoids on plasma insulin. N Engl J Med 274: 1237–1241
Baker L, Kaye R, Haque N (1969) Metabolic homeostasis in juvenile diabetes mellitus. Increased ketone responsiveness to epinephrine. Diabetes 18: 421–427
Schade DS, Eaton RP (1975) Glucagon regulation of plasma ketone body concentration in human diabetes. J Clin Invest 56: 1340–1344
Schade DS, Eaton RP (1978) Modulation of basal ketone body concentration by cortisol in diabetic man. J Clin Endocrinol Metab 47: 519–528
Schade DS, Eaton RP (1978) The regulation of plasma ketone body concentration by counter-regulatory hormones in man. II. Effects of growth hormone in diabetic man. Diabetes 27: 916–924
Willms B, Böttcher M, Wolters V, Sakamoto N, Söling HD (1969) Relationship between fat and ketone body metabolism in obese and nonobese diabetics and nondiabetics during norepinephrine infusion. Diabetologia 5: 88–96
Gerich J, Lorenzi M, Bier D, Schneider V, Tsalikian E, Karam J, Forsham P (1975) Prevention of human diabetic ketoacidosis by somatostatin: Evidence for an essential role of glucagon. N Engl J Med 292: 985–989
Gerich JE, Schneider V, Dippe SE, Langlois M, Noacco C, Karam JH, Forsham PH (1979) Characterization of the glucagon response to hypoglycemia in man. J Clin Endocrinol Metab 38: 77–82
Benson JW Jr, Johnson DG, Palmer JP, Werner PL, Ensinck JW (1977) Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man. J Clin Endocrinol Metab 44: 459–464
Christensen NJ, Alberti KGMM, Brandsborg O (1975) Plasma catecholamines and blood substrate concentrations: Studies in insulin induced hypoglycaemia and after adrenaline infusions. Eur J Clin Invest 5: 415–423
Pfeiffer EF, Thum Ch, Clemens AH (1974) The artificial beta cell. A continuous control of blood sugar by external regulation of insulin infusion (glucose-controlled insulin infusion system). Horm Metab Res 6: 339–342
Statistical Bulletin 40 (Nov–Dec 1959) Metropolitan Life Insurance Company
Waldhäusl W, Bratusch-Marrain P, Dudczak R, Deutsch E (1977) The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics. J Clin Endocrinol Metab 44: 876–883
Waldhäusl W, Frisch H, Haydl H (1974) Elevated insulin binding capacity: incidence and treatment by monocomponent insulin. International Congress Series 316, Excerpta Medica, Amsterdam, pp 56–62
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Science 19: 1161–1174
Trout DL, Estes EH Jr, Friedberg SJ (1960) Titration of free fatty acids of plasma: a study of current methods and a new modification. J Lipid Res 1: 199–202
Williamson DH, Mellanby J (1974) D-(-)-3-Hydroxybutyrate. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse, Vol II. Verlag Chemie, Weinheim, pp 1883–1886
Mellanby J, Williamson DH (1974) Acetatacetat. In: Bergmeyer HU (eds) Methoden der enzymatischen Analyse, Vol II. Verlag Chemie, Weinheim, pp 1887–1890
Porte D Jr (1969) Sympathetic regulation of insulin secretion. Arch Intern Med 123: 252–260
Cohen AS, Vance VK, Runyan JW Jr, Hurwitz D (1960) Diabetic acidosis: An evaluation of the cause, course and therapy of 73 cases. Ann Intern Med 52: 55–86
Hinkle LE Jr, Conger GB, Wolf S (1950) Studies on diabetes mellitus: The relation of stressful life situations to the concentration of ketone bodies in the blood of diabetic and non-diabetic humans. J Clin Invest 29: 754–769
Liljenquist JE, Rabin D (1979) Lack of a role for glucagon in the disposal of an oral glucose load in normal man. J Clin Endocrinol Metab 49: 937–939
Clarke WL, Santiago JV, Kipnis DM (1978) The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus. Diabetes 27: 649–652
Sherwin RS, Fisher M, Hendler R, Felig P (1976) Hyperglucagonemia and blood glucose regulation in normal, obese, and diabetic subjects. N Engl J Med 294: 455–461
Waldhäusl W, Dudczak R, Freyler H, Haydl H (1977) Endocrine and metabolic factors associated with diabetic retinopathy. In: Bajaj JS (ed) Diabetes, International Congress Series 413, Excerpta Medica, Amsterdam, pp 620–628
Sherwin RS, Shamoon H, Hendler R, Sacca L, Eigler N, Malewsky M (1980) Epinephrine and the regulation of glucose metabolism: Effect of diabetes and hormonal interactions. Metabolism 29: 1146–1154
Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P (1979) Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 17: 221–227
Sönksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD (1967) Changes of carbohydrate tolerance in acromegaly with progress of the and in response to treatment. J Clin Endocrinol Metab 27: 1418–1430
Pupo AA, Wajchenberg BL, Schnaider J (1966) Carbohydrate metabolism in hyperadrenocorticism. Diabetes 15: 24–29
Landon J, Wynn V, James VHT (1963) The adrenocortical response to insulin-induced hypoglycaemia. J Endocrinol 27: 183–192
Bloom ME, Mintz DH, Field JB (1969) Insulin-induced post-hypoglycemic hyperglycemia as a cause of “brittle” diabetes. Am J Med 47: 891–903
Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM (1976) The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest 58: 7–15
Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH (1976) Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. J Clin Invest 57: 875–884
Förster H, Haslbeck M, Mehnert H (1972) Metabolic studies following the oral ingestion of different doses of glucose. Diabetes 21: 1102–1108
Pozefsky T, Tancredi RG, Moxley RT, Dupre J, Tobin JD (1976) Metabolism of forearm tissue in man: studies with glucagon. Diabetes 25: 128–135
Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW, Crofford OB, Liddle GW (1974) Effects of glucagon on lipolysis and ketogenesis in normal and diabetic man. J Clin Invest 53: 190–197
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bratusch-Marrain, P., Waldhäusl, W., Grubeck-Loebenstein, B. et al. The role of “diabetogenic” hormones on carbohydrate and lipid metabolism following oral glucose loading in insulin dependent diabetics: Effects of acute hormone administration. Diabetologia 21, 387–393 (1981). https://doi.org/10.1007/BF00252687
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00252687